Early switch from run-in with targeted to immunotherapy in advanced BRAFV600-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial - Livingstone, Elisabeth; Gogas, H. J.; Kandolf, L.; Meier, F.; Eigentler, T. K.; Ziemer, M.; Terheyden, P.; Gesierich, A.; Herbst, R. A.; Kähler, K. C.; Ziogas, D. C.; Mijušković, Ž.; et al. (ESMO open, 2025)
Online verfügbar: 8. Mai 2025, Artikelversion: 8. Mai 2025